NASDAQ:NVAXNovavax Stock Price, Forecast & News

Novavax's stock was trading at $10.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVAX stock has increased by 338.1% and is now trading at $46.04. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Novavax.

Novavax is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Novavax.

Novavax, Inc. (NASDAQ:NVAX) issued its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.67) by $0.09. The biopharmaceutical company earned $3.38 million during the quarter, compared to analyst estimates of $3.50 million. During the same period in the previous year, the company posted ($2.20) earnings per share. View Novavax's earnings history.

Novavax's stock reverse split before market open on Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of Novavax stock prior to the reverse split would have 5 shares after the split.

6 Wall Street analysts have issued 12 month target prices for Novavax's stock. Their forecasts range from $15.00 to $61.00. On average, they anticipate Novavax's stock price to reach $43.25 in the next twelve months. This suggests that the stock has a possible downside of 6.1%. View analysts' price targets for Novavax.

News headlines about NVAX stock have been trending negative on Saturday, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Novavax earned a coverage optimism score of -2.5 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutNovavax.

Some companies that are related to Novavax include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Egalet (EGLT), EXACT Sciences (EXAS), Palo Alto Networks (PANW), Akebia Therapeutics (AKBA), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Cara Therapeutics (CARA), NVIDIA (NVDA) and AT&T (T).

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

Novavax's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (2.98%), Geode Capital Management LLC (1.06%), State Street Corp (1.00%), Invesco Ltd. (0.90%), JPMorgan Chase & Co. (0.75%) and Nuveen Asset Management LLC (0.33%). Company insiders that own Novavax stock include Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Rachel K King. View institutional ownership trends for Novavax.

NVAX stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Geode Capital Management LLC, Federated Hermes Inc., and UBS Group AG. Company insiders that have sold Novavax company stock in the last year include Gregory M Glenn, John A Herrmann III, John Trizzino, and Michael A Mcmanus Jr. View insider buying and selling activity for Novavax.

NVAX stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., JPMorgan Chase & Co., State Street Corp, Nuveen Asset Management LLC, Advisor Group Holdings Inc., Creative Planning, Bank of New York Mellon Corp, and AXA. Company insiders that have bought Novavax stock in the last two years include Gregory M Glenn, and Rachel K King. View insider buying and selling activity for Novavax.

Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of NVAX stock can currently be purchased for approximately $46.04.

Novavax has a market capitalization of $2.67 billion and generates $18.66 million in revenue each year. The biopharmaceutical company earns $-132,690,000.00 in net income (profit) each year or ($5.80) on an earnings per share basis. Novavax employs 373 workers across the globe.

The official website for Novavax is www.novavax.com.

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]